Nuria Esforzado

Nuria Esforzado is a nephrologist and renal-transplant specialist associated with Barcelona’s Hospital Clinic and Universitat de Barcelona. Her contribution to the volume is not that of a fictional protagonist but of a named medical authority whose authorship helps organize the book’s central problem: hepatitis C is simultaneously a viral infection, a systemic disease with renal manifestations, a complication of dialysis, and a factor in the allocation and timing of kidney transplantation. Through her chapters and collaborations, Esforzado appears at the point where laboratory classification, clinical judgment, and transplant policy become one continuum of care.

Identity and Professional Setting

Nuria Esforzado is identified as a contributor to the chapter “Treatment of Hepatitis C in Dialysis Patients,” written with Josep M. Campistol. The authors are affiliated with the Department of Nephrology and Renal Transplantation at Hospital Clinic, Universitat de Barcelona, and IDIBAPS in Barcelona. This setting places Esforzado within a specialist environment concerned with both renal replacement therapy and transplantation, rather than with liver disease in isolation.

Her professional identity is also visible in the volume’s broader network of transplant medicine. Esforzado is listed among the authors of “Renal Transplantation from Donors with a Positive Serology for Hepatitis C,” alongside Beatriz Domínguez-Gil, Amado Andrés, Josep M. Campistol, and Jose M. Morales. The chapter’s subject extends her role from treating infected dialysis patients to assessing whether organs from hepatitis C-positive donors can be used for selected recipients. Her work therefore joins bedside treatment to questions of organ scarcity, infection transmission, and acceptable transplant risk.

Clinical Focus on Treatment in Dialysis

In the treatment chapter, Esforzado’s subject is a population for whom ordinary antiviral decisions cannot simply be copied from the general population. The recommendations emphasize that therapy for patients with chronic renal disease must be individualized according to the expected benefits and risks, life expectancy, the possibility of receiving a kidney transplant, and coexisting illnesses. Treatment is thus presented as a decision shaped by the patient’s renal status and future transplant prospects, not merely by the presence of detectable virus.

The chapter describes conventional interferon and reduced-dose pegylated interferon as treatment options under KDIGO guidance. For genotype 1 and genotype 4 infection, treatment may last 48 weeks when there is a rapid fall in viral load by week 12; for genotype 2 and genotype 3 infection, the stated duration is 24 weeks. Ribavirin is not generally recommended for patients on dialysis, although it may be combined with low-dose interferon under strict monitoring for anemia. These details show the practical tension at the center of Esforzado’s clinical field: antiviral eradication is desirable, but drug toxicity and impaired renal clearance alter the conditions under which it can safely be attempted.

The same evidence places treatment within a larger diagnostic sequence. Active chronic infection requires both anti-HCV positivity and HCV RNA positivity for more than six months, while noninvasive methods such as FibroScan can help evaluate liver stiffness and permit ongoing fibrosis follow-up. The disease is not confined to the liver: hepatitis C can induce autoimmune, dermatological, and renal disease, and mixed cryoglobulinemia may present with proteinuria, hematuria, impaired kidney function, nephritic syndrome, or nephrotic syndrome. Esforzado’s treatment perspective consequently rests on a layered account of disease, distinguishing antibody evidence, active viremia, hepatic injury, and extrahepatic renal complications.

Transplantation, Waiting, and Clinical Timing

Esforzado’s transplant-related work treats time as a clinical variable. Candidates for kidney transplantation with active hepatitis C require screening and staging of liver disease, and patients with advanced or decompensated cirrhosis may need referral for simultaneous liver-kidney transplantation rather than kidney-alone transplantation. The pretransplant evaluation therefore determines not only whether treatment is indicated but also which transplant pathway remains medically appropriate.

Patients who remain on a kidney waiting list must be monitored because waiting itself can permit liver disease to progress. In one cited group of 13 patients who underwent repeat liver biopsy while still awaiting transplantation, eight, or 62 percent, showed worsening liver histology; by contrast, worsening was found in seven of 31, or 23 percent, of follow-up biopsies obtained after transplantation. The recommended surveillance interval varies with fibrosis: repeat biopsy every five years for Metavir stage 1 or 2 disease, and after three years for stage 3 fibrosis. Progression to early or established cirrhosis can remove a patient from the kidney-only list and redirect the case toward liver-team assessment for simultaneous transplantation.

The question of when to eradicate the virus is equally consequential. There is no universal consensus on treating active viremia before kidney transplantation, but achieving a sustained virologic response before transplantation may reduce the risk of post-transplant diabetes and immune-complex-mediated glomerular disease in the allograft. Most patients who achieve sustained virologic response before transplantation do not relapse after immunosuppression, whereas interferon use after transplantation is associated with increased allograft-rejection risk. The resulting logic favors concentrating efforts to eliminate hepatitis C before transplantation whenever treatment is feasible.

Hepatitis C-Positive Donor Kidneys

The donor-serology chapter places Esforzado within a debate created by the shortage of transplantable organs. At the end of 2009, the European Union had approximately 63,000 patients waiting for an organ while about 28,000 transplant procedures were performed during that year; in the United States, nearly 111,000 people were registered on the waiting list in May 2011, with roughly 28,000 procedures performed annually. In this setting, the use of kidneys from hepatitis C-positive donors becomes a question of whether a potentially usable organ should be discarded when a carefully selected recipient might benefit.

The chapter acknowledges that kidney transplantation from hepatitis C-positive donors remains controversial. Some centers never accept such kidneys, and some countries impose technical or legal restrictions. Yet transmission through transplantation is a recognized hazard, while continued dialysis also carries substantial risk. For end-stage renal disease patients with active hepatitis C who cannot undergo antiviral treatment, refuse it, fail to respond, or withdraw because of adverse effects, transplantation may offer a more favorable course than remaining on dialysis. A hepatitis C-positive kidney could therefore be offered to an appropriately selected hepatitis C-positive recipient, with the possible advantage of shortening the waiting period.

This policy is constrained by the changing epidemiology of hepatitis C. Expanded antiviral treatment and universal preventive strategies have reduced active infection among patients with end-stage renal disease and among those awaiting transplantation, leaving hepatitis C-positive kidneys without enough suitable recipients. The cited analysis found that these kidneys were 2.60 times more likely to be discarded than hepatitis C-negative kidneys. Esforzado’s transplant perspective thus exposes a structural contradiction: improved prevention and treatment reduce the pool of infected recipients even as organ scarcity makes discarding an otherwise usable kidney increasingly difficult to justify.

Collaborative and Intellectual Significance

Esforzado’s work is embedded in the book’s larger institutional response to hepatitis C. The volume presents hepatitis C as a major worldwide health problem affecting more than 150 million people and as a systemic disease requiring cooperation among nephrology, dialysis, transplantation, hepatology, virology, and public-health organizations. It also situates clinical practice within the KDIGO clinical practice guidelines for prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease, described as the most comprehensive contribution on the topic at the time.

The therapeutic landscape described alongside Esforzado’s work was already changing. Pegylated interferon and ribavirin produced sustained virologic response in more than half of patients with chronic infection, but more than half of genotype 1-infected patients did not achieve that outcome. Direct-acting antiviral drugs, including protease and polymerase inhibitors, were developed to target the viral cycle; first-generation telaprevir and boceprevir increased sustained virologic response rates in genotype 1 infection by approximately 20 to 30 percent. For dialysis and transplant patients, however, the existence of new drugs did not erase questions of anemia, adverse effects, cost, compliance, resistance, drug interactions, and the danger of post-transplant interferon-induced rejection.

Esforzado’s significance lies in this refusal to separate virology from institutional life. Her authorship follows hepatitis C from anti-HCV and HCV RNA testing to fibrosis assessment, from dialysis-unit management to waiting-list surveillance, and from pretransplant treatment to the ethically charged use of hepatitis C-positive donor kidneys. She represents a form of specialist knowledge that is both classificatory and practical: it distinguishes resolved infection from active infection, measures the changing severity of liver disease, identifies renal manifestations such as cryoglobulinemic glomerulonephritis, and converts those distinctions into decisions about treatment, listing, transplantation, and risk.